Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus"), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) ("Progenics"), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that Lantheus has entered into a Support Agreement (the "Support Agreement") with Velan Capital ("Velan") in connection with the proposed merger of Lantheus and Progenics.
Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus"), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) ("Progenics"), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that they have decided to reschedule their respective special meetings of stockholders (the "Special Meetings") to vote on matters related to the proposed merger of Lantheus and Progenics from April 28, 2020, to June 16, 2020.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 25) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) (Cowen ...
Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus" or the "Company"), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents announced today that its preliminary unaudited revenue for the fiscal first quarter ended March 31, 2020 will be near the top end of previously disclosed guidance range issued on February 25, 2020.
Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference at 3:00 p.m. ET on Tuesday, May 19.
NEW YORK, NY / ACCESSWIRE / February 25, 2020 / Lantheus Holdings, Inc. (NASDAQ:LNTH) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 25, 2020 ...
Today we'll look at Lantheus Holdings, Inc. (NASDAQ:LNTH) and reflect on its potential as an investment. Specifically...
Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, April 30, 2020, to discuss its financial and operating results for the first quarter of 2020.
To the annoyance of some shareholders, Lantheus Holdings (NASDAQ:LNTH) shares are down a considerable 31% in the last...
Image source: The Motley Fool. Lantheus Holdings Inc (NASDAQ: LNTH)Q1 2020 Earnings CallApr 30, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, ladies and gentlemen.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ: PGNX) in connection with the proposed acquisition of the company by Lantheus Holdings, Inc. ("LNTH") (NASDAQ: LNTH). Under the terms of the acquisition agreement, PGNX shareholders will receive 0.31 shares of LNTH for each PGNX share they own, representing implied per-share merger consideration of only $3.96 based on LNTH's May 26, 2020 closing price of $12.77.
Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today reported financial results for its first quarter ended March 31, 2020.
Q1 2020 Lantheus Holdings Inc Earnings Call
Q4 2019 Lantheus Holdings Inc Earnings Call
In response to continued public health concerns about in-person gatherings given the coronavirus/COVID-19 outbreak, the Board of Directors of Lantheus Holding, Inc. (the "Company") (NASDAQ:LNTH) has determined to change the format of the company’s 2020 Annual Meeting of Stockholders scheduled for Thursday, April 23, 2020 at 11:00 a.m. (Eastern Time) from in-person to virtual-only.
Boston Scientific Corp. became one of the first local medical device firms to cut executive and employee pay as the COVID-19 outbreak cuts into surgical product sales.
Shares of Lantheus Holdings (NASDAQ:LNTH) remained unaffected at $14.03 after the company reported Q1 results.Quarterly Results Earnings per share rose 28.57% over the past year to $0.36, which beat the estimate of $0.27.Revenue of $90,704,000 rose by 4.85% year over year, which missed the estimate of $91,200,000.Guidance Lantheus Holdings hasn't issued any earnings guidance for the time being.Lantheus Holdings hasn't issued any revenue guidance for the time being.Details Of The Call Date: Apr 30, 2020View more earnings on LNTHTime: 12:02 PM ETWebcast URL: https://edge.media-server.com/mmc/p/dj4madogTechnicals 52-week high: $29.80Company's 52-week low was at $8.67Price action over last quarter: down 13.93%Company Profile Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. The company's portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacy and directly to hospitals and clinics predominantly in the United States.See more from Benzinga * Amalgamated Bank: Q1 Earnings Insights * 15 Consumer Cyclical Stocks Moving In Thursday's Pre-Market Session * 9 Real Estate Stocks Moving In Thursday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Last week saw the newest full-year earnings release from Lantheus Holdings, Inc. (NASDAQ:LNTH), an important milestone...
To the annoyance of some shareholders, Lantheus Holdings (NASDAQ:LNTH) shares are down a considerable 35% in the last...
Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference at 10:30 a.m. ET on Wednesday, June 3.